X-linked severe combined immunodeficiency IXSCID) is a lethal disease caused by a defect in the gene encoding the common y chain (yJ of the receptor for interleukin-2 (IL-2). IL-4, IL-7, IL-9, and IL-15. Allogeneic bone marrow transplantation, the current therapy of choice for this defect, is often complicated by graft-versus-host disease andlor incomplete reconstitution of B-lymphocyte functions. Correction of the gene defect at the level of the autologous lymphohematopoietic progenitors could therefore represent an improvement in the medical management of these patients. To study the feasibility of a gene therapy approach for XSCID, a retroviral vector expressing yc was used to trans--LINKED SEVERE combined immunodeficiency x (XSCID) accounts for at least half of the cases of this most lethal primary immunodeficiency. XSCID males generally present with recurrent severe infections and failure to thrive; T cells in blood and lymphoid organs are extremely infrequent or absent, whereas B cells are usually present, yet functionally impaired. As a result of the defect of both humoral and cell-mediated immunity, XSCID patients usually succumb early in life to overwhelming opportunistic infections. Isolation in aseptic environments and various antibiotic prophylaxis regimens do not represent a realistic Iongterm care option for these patients. In absence of an adequate alternative treatment, allogeneic bone marrow transplantation (BMT) has become the therapeutic intervention of choice. However, BMT can be associated with severe complications and even successfully transplanted patients often experience acute or chronic graft-versus-host disease (GVHD) and/or incomplete reconstitution of humoral immunity.14 XSCID has been found to be caused by mutations in the gene encoding for the common y chain ( y c ) of the receptors for interleukin-2 (IL-2), IL-4, IL-7, IL-9, and IL-15. The defect was originally described in the receptor for IL-2 (IL-2R),516 in which it results in the loss of high-affinity cytokine bindingT8 a block of JAK3 activation: and deficient growth signaling.* Identification of the specific genetic defect responsible for XSCID has made it possible to explore a gene therapy approach for this disease. In this study, we evaluated the feasibility of the genetic correction of XSCID by means of retroviral-mediated gene transfer of the 7,-cDNA into Epstein-Barr virus (EBV)-transformed B-cell lines derived from XSCID patients, and we show that successful stable expression of the transgene results in correction of cytokinemediated cellular functions.
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MATERIAFS AND METHODS
Peripheral blood obtained with informed consent from three XSCID patients was used to establish B-cell lines (BCLs) by standard immortalization with EBV. All patients (nos. 5, 18, and 38) had typical clinical presentation of XSCID and carried a mutation occuning in the coding sequence of ye that abrogated expression of 7,-mRNA as tested by Northem blot analysis (Puck et a16 and Puck PA3 17 cells were transfected with plasmid DNA by standard calcium-phosphate c~precipitation.'~ PA317-derived supernatants were used to transduce PG13 cells and the retroviral particles were thus packaged with the envelope from the gibbon-ape leukemia virus (GALV) were used for transduction of XSCID BCLs, following an optimized transduction protocol combining low-temperature incubation, centrifugation, and metabolic induction of the GLVR 1 rettoviral receptor as de~cribed.'~ Transfected and transduced cells were selected in the neomycin-analogue G4 18 (Geneticin; Life Technologies, Gaithersburg, MD; 0.8 to 1 .O mg/mL active metabolite).
Patients.
TUGh4," a rat monoclonal antibody (MoAb) specific for human y c , was used to detect the presence hnmunoprecipitnri? and irnmurroh/or. Cells (5 to 10 x 10') were cultured in medium containing 0.5% FBS or without FBS for 4 hours, stimulated with IL-2 (1,000 UlmL) or IL-4 (200 UlmL) for 15 minutes, and lysed in lysis buffer (300 mmol/L NaCI, SO mmoll L Tris-HCI. 2 mmol/L EDTA, 0.5% Brij 96.2.5 pmol/L p-nitrophenyl p'-guanidino-benzoate, 10 pglmL aprotinin, I0 pglmL leupeptin, and 200 pmol/L sodium orthovanadate). Cell lysates were centrifugated at 12,000,q and postnuclear supernatants were immunoprecipitated with a rabbit polyclonal antibody (polyAb) raised against JAK3 protein tyrosine kinase (aJAK3)" or JAKl (aJAKI; Upstate Biotechnology, Lake Placid, NY). Immunoprecipitated complexes were boiled and subjected to polyacrylamide gel electrophoresis (PAGE), electrotransferred to nylon mebranes (Immobilon-P Millipore, Bedford, MA), and immunoblotted with mouse MoAb antiphosphotyrosine (a PY, clone 4G10; Upstate Biotechnology). aJAK3, or aJAKl (Transduction Labs, Lexington, KY) Abs. as described."' Detection of immunocomplexes was performed by enhanced chemiluminescence (ECL; Amersham Life Science, Arlington Heights, IL).
Cells were cultured in 0.5% FBS for 18 to 24 hours and then seeded to 96-well plates (triplicates of 2 x IO4 cellslwell) in RPMI 1640 medium containing serially increasing concentrations of IL-2. Cells were incubated at 37"C, 5 % COz, for 30 hours and pulsed with 'H-thymidine ( I pCilwell; Dupont-NEN, Boston, MA) for an additional 6 hours. Cells were then harvested using an automated cell harvester (Wallac, Uppsula, Sweden), and incorporated radioactivity was determined by a scintillation betacounter (Wallac PA3 17-derived retroviral vector supernatants were used to transduce PG13 cells, thus generating a new line producing a vector packaged into the gibbon-ape leukemia envelope (GC2Ry-GALV) that was used in subsequent transduction experiments on XSCID BCLs.
Northern blot analysis showed that GC2Ry vector expressed high levels of yc mRNA in both PA3 17-and PG 13-derived producer lines and that GC2Ry-GALV vector was able to efficiently confer yc mRNA expression to all transduced XSCID BCLs (data not shown).
We then evaluated the membrane expression of the transgenic yc by flow cytometric analysis. BCLs from the three XSCID patients did not show detectable surface expression of yc when subjected to immunostaining with TUGh4 before retroviral-mediated gene transfer. After transduction and G418 selection, the same XSCID BCLs were shown to newly express levels of surface yc comparable to BCLs from normal donors (Fig 2) . XSCID BCLs transduced
The full-length yc cDNA" was subcloned into pSAM-EN retroviral cassette using Not I and Xho I sites to generate pGC2Ry (Fig I) . First, a GC2Ry retroviral producer line was obtained by transfection of pGC2Ry into PA3 17 cells; subsequently, Retroviral-mediated expression qf y,.. For Analwis of cytokine-mediated phosphorylation of JAK3 arid JAKI. To determine whether we could reconstitute normal signaling in the y,-transduced lines, BCLs derived from normal donors and XSCID patients were stimulated with IL-2 or IL-4, and the signal transduction via yc was assayed as phosphorylation of JAKl and JAK3 tyrosine kinases. Figure 3A shows the results of a typical experiment using one XSCID BCL. analyzed before and after gene transfer. Untransduced XSCID cells (lanes 4 through 6) do not show phosphorylation of JAK3 after cytokine stimulation, whereas after yc gene transfer (lanes 7 through 9), the signal transduction induced by IL-2 and IL-4 is reconstituted, yielding phosphorylation levels of JAK3 comparable to those observed in BCLs from normal control (lanes I through 3). 
4-JAK3
(w-1-1
Similar reconstitution of JAK3 phosphorylation was observed in the two other y,-transduced XSCID BCLs studied, but not in XSCID BCLs transduced with the SAM-EN control retroviral vector (data not shown). In addition, IL-2 or IL-4 stimulation of normal control and y,-transduced XSCID BCLs induced substantial phosphorylation of JAKl (Fig 3B.  lanes 1 through 3 and 7 through 9, respectively) , in comparison to untransduced parental XSCID BCLs (lanes 4 through 6) and SAM-EN-transduced control BCLs (data not shown).
BCLs from normal donors, untransduced XSCID BCLs, and y,-transduced XSClD BCLs were exposed to increasing conccntrations of IL-2 in the presence or absence of IL-2-neutralizing or isotype control antibodies. After 36 hours of incubation, cell proliferation was assayed by 'H-thymidine incorporation. growth, whereas normal control and 7,-transduced XSCID BCLs were able to respond to cytokine stimulation by significantly increasing the uptake of tritiated thymidine. The addition of an IL-2 neutralizing MoAb inhibited E-2-dependent cell proliferation, whereas the presence of an irrelevant isotype-matched Ig did not. XSCID BCLs transduced with the SAM-EN control retroviral vector did not show increased cell proliferation when subjected to IL-2 stimulation (data not shown).
DISCUSSION
XSCID-affected boys lack both cellular and humoral defense mechanisms against pathogens, they rapidly become severely ill, and, if not treated, usually die from overwhelming infection within the first 2 years of life.',' In the last 25 years, the application of allogeneic BMT to primary immunodeficiency patients, and to XSCID boys in particular, has shown that it is possible to achieve immunologic reconstitution in these patients?20'22 However, the rarity of HLAmatched donors, the threat of GVHD reactions, and incomplete immune reconstitution of B lymphocyte function make the development of alternative therapies highly desirable. The demonstration that cellular therapy can be curative for this disease suggests that gene correction and reinfusion of autologous hematopoietic stem cells could also theoretically provide a means to reconstitute the function of the immune system of XSCID patients. This approach would eliminate the need for an allogeneic bone marrow donor and thus avoid the risk of complications related to the infusion of allogeneic In the present work, we have shown that retroviral-mediated gene transfer of the 7,-cDNA into BCLs of XSCID patients can reconstitute the missing component of the IL-2 and IL-4 receptors in these cells. The y c was expressed on the cell surface at levels comparable to normals and was able to induce phosphorylation of the JAKl and JAK3 kinases upon stimulation with IL-2 and IL-4. Furthermore, 7,-transduced cells acquired the ability to proliferate in response to IL-2. All these features were missing in untransduced XSCID BCLs and in cells transduced with a control retroviral vector carrying only the neoR gene. Taken together, these results suggest that reconstitution of functional multiple chain receptors (IL-2R, IL4R, and possibly IL-7R, IL-gR, and IL-15R that also share 7,34-39) is achievable in XSCID cells using retroviral vectors and show the theoretical feasibility of a gene therapy approach for XSCID.
As discussed above, and in contrast to the first ADAdeficient patients treated by Blaese protein can be deleterious for differentiation and function of mature hematopoietic elements. Mice with targeted deletion of the yc have recently been generated41-43 and will be extremely useful to study whether new vectors designed to provide regulated expression of yc gene product (eg, containing lymphoid-specific promoter sequences) will be needed for use in clinical applications. However, preliminary studies conducted in miceu have shown expression of yc throughout all stages of hematopoietic development.
Molecular analysis of the defects in XSCID patients have shown that mutations are found scattered throughout the yc coding and splice These mutations either can abrogate expression of the yc or cause changes of one or few amino acids or can result in intracellular truncations that are still compatible with low or even normal levels of cell surface expression of the yc protein7.8.45.46 (Puck et al, manuscript submitted). Yet, with the exception of a single case reported to date,'" all mutations severely hamper yc function, generating the XSCID phenotype. Attempting gene therapy in those patients presenting an abnormal protein could result in poor correction of the XSCID phenotype because of a dominant negative effect of the endogenous defective protein. Work is in progress to investigate to what extent signal transduction to JAK3 can be negatively affected by the coexpression of mutated and normal yc molecules to determine whether such a gene addition-based therapy is likely to be limited to use in that subgroup of XSCID patients whose genetic defects lead to the complete absence of the mutant protein,
